Literature DB >> 33770101

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.

Paul T Martin1,2, Deborah A Zygmunt1, Anna Ashbrook1, Sonia Hamilton3, Davin Packer4, Sharla M Birch5, Amanda K Bettis5, Cynthia J Balog-Alvarez5, Lee-Jae Guo5, Peter P Nghiem5, Joe N Kornegay5.   

Abstract

We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3-6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x1014vg/kg and one at 6x1014vgkg. The 2x1014vg/kg dose led to transduction of regions of the heart with 1-3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25-0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20-35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength.

Entities:  

Year:  2021        PMID: 33770101      PMCID: PMC7997012          DOI: 10.1371/journal.pone.0248721

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  82 in total

1.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

2.  Eccentric contractions induce rapid isometric torque drop in dystrophin-deficient dogs.

Authors:  Christopher J Tegeler; Robert W Grange; Daniel J Bogan; Chad D Markert; Doug Case; Joe N Kornegay; Martin K Childers
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

3.  Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy.

Authors:  R M Grady; H Teng; M C Nichol; J C Cunningham; R S Wilkinson; J R Sanes
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

4.  Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.

Authors:  Joe N Kornegay; Juan Li; Janet R Bogan; Daniel J Bogan; Chunlian Chen; Hui Zheng; Bing Wang; Chunping Qiao; James F Howard; Xiao Xiao
Journal:  Mol Ther       Date:  2010-06-01       Impact factor: 11.454

5.  Definition of pre- and postsynaptic forms of the CT carbohydrate antigen at the neuromuscular junction: ubiquitous expression of the CT antigens and the CT GalNAc transferase in mouse tissues.

Authors:  Kwame Hoyte; Christine Kang; Paul T Martin
Journal:  Brain Res Mol Brain Res       Date:  2002-12-30

6.  Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature.

Authors:  Paul Gregorevic; Brian R Schultz; James M Allen; Jeffrey B Halldorson; Michael J Blankinship; Norman A Meznarich; Christian S Kuhr; Caitlin Doremus; Eric Finn; Denny Liggitt; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

7.  Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies.

Authors:  B A Valentine; B J Cooper; A de Lahunta; R O'Quinn; J T Blue
Journal:  J Neurol Sci       Date:  1988-12       Impact factor: 3.181

8.  Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

Authors:  Caroline Le Guiner; Marie Montus; Laurent Servais; Yan Cherel; Virginie Francois; Jean-Laurent Thibaud; Claire Wary; Béatrice Matot; Thibaut Larcher; Lydie Guigand; Maeva Dutilleul; Claire Domenger; Marine Allais; Maud Beuvin; Amélie Moraux; Johanne Le Duff; Marie Devaux; Nicolas Jaulin; Mickaël Guilbaud; Virginie Latournerie; Philippe Veron; Sylvie Boutin; Christian Leborgne; Diana Desgue; Jack-Yves Deschamps; Sophie Moullec; Yves Fromes; Adeline Vulin; Richard H Smith; Nicolas Laroudie; Frédéric Barnay-Toutain; Christel Rivière; Stéphanie Bucher; Thanh-Hoa Le; Nicolas Delaunay; Mehdi Gasmi; Robert M Kotin; Gisèle Bonne; Oumeya Adjali; Carole Masurier; Jean-Yves Hogrel; Pierre Carlier; Philippe Moullier; Thomas Voit
Journal:  Mol Ther       Date:  2014-08-04       Impact factor: 11.454

9.  Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice.

Authors:  B L Patton; J H Miner; A Y Chiu; J R Sanes
Journal:  J Cell Biol       Date:  1997-12-15       Impact factor: 10.539

Review 10.  Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

Authors:  Joe W McGreevy; Chady H Hakim; Mark A McIntosh; Dongsheng Duan
Journal:  Dis Model Mech       Date:  2015-03       Impact factor: 5.758

View more
  2 in total

1.  Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE Myopathy.

Authors:  Stella Mitrani-Rosenbaum; Lena Yakovlev; Michal Becker Cohen; Zohar Argov; Yakov Fellig; Avi Harazi
Journal:  J Neuromuscul Dis       Date:  2022

2.  A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2.

Authors:  Kevin M Flanigan; Tatyana A Vetter; Tabatha R Simmons; Megan Iammarino; Emma C Frair; Federica Rinaldi; Louis G Chicoine; Johan Harris; John P Cheatham; Sharon L Cheatham; Brian Boe; Megan A Waldrop; Deborah A Zygmunt; Davin Packer; Paul T Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-09-02       Impact factor: 5.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.